Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The business case for cell and gene therapies

Nature Biotechnology volume 32, pages 1192–1193 (2014)Cite this article

Subjects

To the Editor

Cell and gene therapies for ailments ranging from inherited to infectious diseases have been developed over the past 20 years. In spite of drawbacks during their early development, they have recently been showing sustained clinical benefits. Two gene therapy products have reached the market1,2, and more are expected to be licensed in the near future. In light of this promising progress, there have been discussions about how such therapies will be reimbursed once they have become standard medical practice.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ylä-Herttuala, S. Mol. Ther. 20, 1831–1832 (2012).

    Article  Google Scholar 

  2. Xin, H. Science 314, 1233 (2006).

    Article  Google Scholar 

  3. Brennan, T.A. & Wilson, J.M. Nat. Biotechnol. 32, 874–876 (2014).

    Article  CAS  Google Scholar 

  4. Cook, J.P., Vernon, J.A. & Manning, R. Pharmacoeconomics 26, 551–556 (2008).

    Article  Google Scholar 

  5. Neumann, P.J., Chambers, J.D., Simon, F. & Meckley, L.M. Health Aff. (Millwood) 30, 2329–2337 (2011).

    Article  Google Scholar 

  6. Candotti, F. et al. Blood 120, 3635–3646 (2012).

    Article  CAS  Google Scholar 

  7. Faulkner, E. et al. Value Health 15, 1162–1171 (2012).

    Article  Google Scholar 

  8. Abou-El-Enein, M. et al. Cytotherapy 15, 362–383 (2013).

    Article  Google Scholar 

  9. Abou-El-Enein, M., Bauer, G., Reinke, P., Renner, M. & Schneider, C.K. Trends Mol. Med. 20, 632–642 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine, Campus Virchow, Berlin, Germany

    Mohamed Abou-El-Enein & Petra Reinke

  2. Department of Nephrology and Internal Intensive Care, Charité University Medicine, Campus Virchow, Berlin, Germany

    Mohamed Abou-El-Enein & Petra Reinke

  3. University of California, Davis, Institute For Regenerative Cures, Sacramento, California, USA

    Gerhard Bauer

Authors
  1. Mohamed Abou-El-Enein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerhard Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Petra Reinke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Abou-El-Enein.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abou-El-Enein, M., Bauer, G. & Reinke, P. The business case for cell and gene therapies. Nat Biotechnol 32, 1192–1193 (2014). https://doi.org/10.1038/nbt.3084

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3084

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research